LDN Social Media
Get connected with us on social networks
Low dose naltrexone: Harnessing the body's own chemistry to treat human ovarian cancer
Science Daily
13 July 2011
https://www.sciencedaily.com/releases/2011/07/110712143012.htm
Researchers have discovered that a low dose of the opioid antagonist naltrexone (LDN) markedly suppresses progression of human ovarian cancer transplanted into mice. LDN's antitumor action was comparable to that of chemotherapy (cisplatin, taxol). LDN combined with cisplatin but not taxol had an additive inhibitory action on tumorigenesis. LDN offers a non-toxic and efficacious biologic pathway-related treatment that may benefit patients with this deadly cancer.